Mesaflor

Mesalazine, the active ingredient in Mesaflor, is a Aminosalicylate presented as a rectal formulation for Rectal use. It treats ulcerative colitis and other inflammatory bowel disease in adults. GNH USA supplies Mesaflor as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mesalazine acts locally in the colon to reduce inflammation associated with inflammatory bowel disease. - Ulcerative colitis: diminishes mucosal inflammation and helps maintain remission. - Proctitis: alleviates rectal inflammation and improves bowel symptoms. - Indeterminate colitis: provides anti‑inflammatory effect similar to ulcerative colitis management.

Mesalazine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Abdominal pain or cramping - Nausea or vomiting - Flatulence or bloating - Headache - Mild rash or itching - Diarrhoea

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis, angioedema) - Acute severe colitis or perforation - Blood dyscrasias (e.g., neutropenia, thrombocytopenia) - Renal impairment or interstitial nephritis - Hepatotoxicity or liver enzyme elevation - Pancreatitis

Before initiating therapy, clinicians should consider several safety aspects. - Renal function: monitor serum creatinine and urine output regularly. - Hepatic function: assess liver enzymes before and during treatment. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Severe disease: use with caution in patients with extensive colitis or systemic involvement. - Sulfa allergy: avoid in individuals with known sulfonamide hypersensitivity. - Store at room temperature: keep in the original package, protect from moisture and direct sunlight.

Mesalazine can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Azathioprine or 6‑mercaptopurine: heightened bone‑marrow toxicity. - Cyclosporine: potential additive nephrotoxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate gastrointestinal irritation. - Oral contraceptives: possible reduction in contraceptive efficacy. - Lithium: altered lithium serum levels. - Methotrexate: increased hepatic risk.